Drug intelligence / Profile preview

IDF190400338

Development stage: Preclinical
Lead developer: IlDong Pharmaceutical Co Ltd
Modality: Small Molecules
Administration: Oral

Overview

IDF190400338 is a small-molecule dual modulator of the adenosine A1 and A2A receptors being developed by Ildong Pharmaceutical and its R&D subsidiary, Yunovia, for the treatment of Parkinson's disease. Adenosine receptors are integral to the modulation of dopaminergic signaling within the basal ganglia, a key area affected in Parkinson's disease. By targeting both the A1 and A2A receptor subtypes, the compound aims to improve motor function and potentially offer neuroprotective effects. The drug is currently in the preclinical stage, specifically undergoing IND-enabling studies to support future clinical trials.

Other names: Ildong A1/A2A receptor modulator

Targets

ADORA2A (Adenosine A₂A Receptor)ADORA1 (Adenosine receptor A1 subtype)

Beyond the preview

Go deeper on IDF190400338.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IDF190400338.

Explore the full profile